Curcumin, the major active principle of Curcuma longa, is one of the promising, plant-derived, chemopreventive agents being studied for its anticarcinogenic and antioxidant properties. Hence, in our study, we aimed at testing the antiproliferative efficacy of an o-hydroxyl substituted analog of curcumin, bis demethoxy curcumin analog (BDMC-A), and comparing its efficacy with that of curcumin. BDMC-A was synthesised with a yield of 78% and 98% purity. Hep-2 cells and the MTT cell viability assay were used to examine cell proliferation. LDH assay and cell counts were performed to assess the cytotoxicity and anti-proliferative effects of the compound, respectively. Flow cytometry followed by Western blot were performed to investigate the cell cycle distribution. BDMC-A inhibited cell proliferation at a much lower concentration (IC 50 20 µM) than curcumin (IC 50 50 µM). Similar effects were observed in the LDH release and cell count assays. Flow cytometric studies using propidium iodide showed accumulation of cells in the G0/G1 phase and the arrest was further confirmed by immunoblotting of protein cyclin D1. BDMC-A was more potent in inhibiting the cells at a lower dose when compared with curcumin. Our results showed that the analog of curcumin is likely to possess more efficacy compared with curcumin in inhibiting cancer.
Studies have estimated that genetic factors cause only 5-10% of all human cancers, while the remaining percentage is caused by lifestyle. Extensive preclinical and clinical research has led to substantial progress in understanding the multistep nature of the prolonged tumorigenesis process [1, 2] . Although cancers are characterized by the dysregulation of cell signalling pathways at multiple steps, most current anticancer therapies involve the modulation of a single target. The ineffectiveness, lack of safety, and high cost of monotargeted therapies have led to a lack of faith in these approaches. As a result, increased focus has been shown in developing multitargeted therapies. Many plant-based products, however, accomplish multitargeting. Seven plant derived anti cancer drugs have received Food and Drug Administration (FDA) approval for commercial production [3] . Curcumin {1, 7-bis-(4hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione} is a known potential therapeutic agent for cancer. It is a hydrophobic polyphenol derived from the rhizome of Curcuma longa (turmeric) and is presently emerging as an effective anti-cancer agent. Several studies have shown that curcumin exhibits anticarcinogenic activities. This distinct chemopreventive agent exhibits multiple mechanisms of action, which are the key to its therapeutic potential against cancer [4] [5] [6] [7] . This small molecule is a promising lead compound for structure modification. With the basic structure of curcumin ( Figure 1A ), a new curcuminoid was synthesized with a similar structure, but a different position of the hydroxyl group. This analog, BDMC-A {bis-1, 7-(2-hydroxyphenyl)-hepta-1, 6diene-3, 5-dione} ( Figure 1B) , is an ortho isomer of bis demethoxy curcumin (BDMC). BDMC is the most active curcuminoid isolated from C. longa. The introduction of an hydroxyl group in the ortho position is known to increase the therapeutic activity [8] [9] [10] [11] [12] . The present work was aimed at delineating the antiproliferative efficacy of BDMC-A on laryngeal cancer cells (Hep-2) and to compare its efficacy with that of curcumin.
Figure 1:
Curcumin BDMC-A Hep-2 cells were grown in the presence of varying concentrations of curcumin (15-75 μM) and BDMC-A (10-50 μM) for 24 and 48 h, and cell viability was measured by MTT assay (Figures 2A, 2B ). This revealed that BDMC-A inhibited cell proliferation at less than half the concentration (IC 50 20 µM) of that of curcumin (IC 50 50 µM) at 48h. Hep-2 cells were treated with 10 µM BDMC-A and 25 µM curcumin, and the cell cycle distribution was examined after 24 h of drug treatment. The flow cytometric studies showed accumulation of cells in the G0/G1 phase ( Figure 5 ). BDMC-A showed a 7% increase at 10 µM and curcumin an 11% increase at 25 μM.
Western Blot Analysis for the expression of cyclin D1 showed that there was a decrease in the expression of cyclin D1 in both curcumin and BDMC-A treated cells compared with that of the control. The densitometric readings showed that there was a significant decrease in the expression of cyclin D1 in the BDMC-A group when compared with curcumin. Our results showed that BDMC-A is about two times more potent than curcumin in inhibiting cell proliferation in vitro. Many pharmacological and clinical studies support the fact that curcumin has chemopreventive and antiproliferative activity against a variety of human cancers [13 -17] . The cytotoxicity studies revealed that curcumin inhibits the cell proliferation at 50 µM and BDMC-A at 20 µM, which is a lower concentration for effective inhibition of cells. In the normal cell cycle, cells possess check points as control mechanisms to ensure proper execution of cell cycle events [18] . Numerous studies have indicated that curcumin induces cell cycle arrest in various human cancer cells [19, 20] . The accumulation of cells in G0/G1 was observed after both curcumin and BDMC-A treatment. This shows that both curcumin and BDMC-A control the progression of cells through the cycle by decreasing the S-Phase and arresting cells in the G0/G1 phase of the cell cycle. In our study, cells increased in the G1 phase and decreased in the S phase correspondingly. The cell hold back from G1 to the S phase by curcumin has already been reported, which correlates with our present findings. This is through the mechanism of cell cavitation and chromatin agglutination [21] . In our study, there was a greater accumulation of cells with BDMC-A, indicating its potent cell cycle arresting property.
Cyclin D1 is a nuclear protein required for cell cycle progression from G 1 to S phase transition, in turn leading to DNA synthesis [22] . The cyclin D1 proto-oncogene has been shown to play a critical role in cell proliferation through activation of cyclindependent kinases. It is possible that the antiproliferative effects of curcumin are mediated through inhibition of cyclin D1 expression [23] . In our study, the inhibition of cyclin D1 was higher after BDMC-A treatment, indicating that it is more potent than curcumin in inhibiting cell proliferation. The effective anti-proliferatory effect of BDMC-A may be due to the presence of the ortho hydroxyl group. It is reported that the existence of an ortho hydroxyl group in the benzene ring of BDMC-A is critical for the prevention of TPAinduced skin cancer in mice [9] . In one of the reports, BDMC-A has been shown to possess an anticarcinogenic property against a model for colon cancer [24] . The inhibition of cell proliferation, induction of cytotoxicity, and suppression of cyclin D1 and cell cycle in Hep-2 cells by BDMC-A in this study provides evidence for its potential role in laryngeal cancer treatment; it is likely to be more efficacious than curcumin. Further evaluation might reveal its role on various molecular targets. 
Curcumin analog:
The curcumin analog BDMC-A was synthesized by the method of Dinesh Babu and Rajasekaran [25] .
Cell lines and culture conditions:
The Hep-2 cell line was obtained from NCCS, Pune, India. The cells were maintained in 1× Dulbecco's Modification of Eagle's Medium (DMEM), supplemented with 10% fetal bovine serum (FBS) at 37 o C in a CO 2 incubator in an atmosphere of humidified 5% CO 2 and 95% air. The cells were maintained by routine sub culturing in tissue culture flasks. The culture medium was changed every 48 h and the cells were split when they reached confluence. A range of concentrations of BDMC-A and curcumin were used for the determination of IC 50 .
MTT assay:
The MTT colorimetric assay was performed as described previously [26] . Experiments were performed in 6 replicates in 96-well flat-bottomed culture plates (Falcon). MTT was dissolved in phosphate buffered saline (PBS) at 5 mg/mL. After 24 h of incubation of Hep-2 cells with different concentrations of curcumin and BDMC-A, 20 μL of a 5 mg/mL MTT solution was added and the plate was incubated for 4 h, and the cell pellet was dissolved in 100 μL of DMSO. The amount of colored formazan metabolite formed was determined by absorbance at 570 nm.
Estimation of lactate dehydrogenase:
Lactate dehydrogenase activity was determined by the colorimetric method described previously [27] . After incubation of either curcumin or BDMC-A with cells for 24 and 48 h, the medium (without cells) was removed without disturbing the cells for LDH assay. Briefly, 1 mL of buffered substrate and 0.1 mL of conditioned media were taken and 0.2 mL of water was added and maintained at 37°C. NAD + solution (0.2 mL) was added and incubated at 37°C for 15 min. One mL of DNPH reagent was added and incubated for a further 15 min. Finally, 10 mL of sodium hydroxide (0.4 N) was added and the absorbance read at 440 nm. The result was expressed as percentage leakage, which is proportional to the number of dead cells.
Cell count assay for antiproliferative effect:
The cell suspension was thoroughly mixed with trypan blue and allowed to stand for 2 min. A cover-slip was placed over the 2 chambers of the hemocytometer. Using a Pasteur pipette, 10 μL of the cell suspension was transferred to one of the hemocytometer chambers.
The solution was passed under the cover slip by capillary action and made to fill the chamber. The hemocytometer was examined using an inverted microscope at 10X magnification. Both viable (opaque) and non-viable (blue-stained cells) cells were counted separately.
Cell cycle analysis:
To determine the effect of curcumin and BDMC-A on the cell cycle, Hep-2 cells (2 × 10 6 cells) were treated with curcumin and BDMC-A at different doses for 24 h and fixed with 70% ethanol. After overnight incubation at −20°C, cells were washed with PBS prior to staining with propidium iodide (10 mg/mL PI; 0.5% Tween-20; 0.1% RNase in 0.01 M phosphate buffered saline pH 7.2). The cells were analyzed using BD FACS Canto™ (BD, Singapore) and data were analyzed using BD FACS Diva software (BD Biosciences, CA).
Western blot analysis for cyclin D1 expression:
Western blot analysis was carried out as described previously [28] . Cells were homogenized and lysed in RIPA buffer (150 mM NaCl, 50 M Tris, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.4). Protein concentration was determined using Bradford reagent (Sigma-Aldrich) and lysates were resolved on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels. The proteins were then electro-transferred onto a polyvinylidenedifluoride (PVDF) membrane. After blocking with 5% non-fat milk in Tris-buffered saline (TBS, 0.1M, pH 7.4), blots were incubated with primary antibody (mouse monoclonal cyclin D1 antibody) at 4 o C overnight. Protein abundance of -act served as a control for protein loading, and was determined with mouse monoclonal -actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were incubated with secondary antibody, HRP-conjugated goat anti-IgG (Santa Cruz Biotechnology, Santa Cruz, CA), diluted at an appropriate dilution in 1% BSA, for 2 h at room temperature. Protein bands were detected by the enhanced chemiluminescence method (ECL, Pierce, Rockford, IL). Chemi Doc Imaging System (Bio-Rad, USA) was used to detect signals.
Statistical analysis:
All the data were analyzed using the SPSS 7.5 -Windows Students version software. For all the measurements, oneway ANOVA followed by Tukey's test was used to assess the statistical significance between groups. A statistically significant difference was considered at the level of p ≤ 0.05.
